Comparative Pharmacology
Head-to-head clinical analysis: FOSPHENYTOIN SODIUM versus VIGAFYDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FOSPHENYTOIN SODIUM versus VIGAFYDE.
FOSPHENYTOIN SODIUM vs VIGAFYDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Fosphenytoin is a water-soluble prodrug of phenytoin. It is converted to phenytoin, which stabilizes neuronal membranes by blocking voltage-gated sodium channels, thereby inhibiting repetitive firing of action potentials and reducing seizure propagation.
Irreversible inhibitor of GABA transaminase, increasing brain GABA levels.
Loading dose: 15-20 mg PE/kg IV at 100-150 mg PE/min; maintenance: 4-6 mg PE/kg/day IV divided every 8-12 hours.
Adults: 50 mg/kg/day orally divided twice daily; maximum dose 3 g/day.
None Documented
None Documented
The terminal elimination half-life of fosphenytoin is approximately 15 minutes (range 8-30 minutes) following IV administration; however, the half-life of the active metabolite phenytoin is 20-30 hours (dose-dependent) in adults, requiring careful monitoring for accumulation.
Terminal elimination half-life is 6-8 hours in adults; in neonates, it is prolonged to 16-20 hours due to immature renal function.
Renal excretion of inactive metabolites (primarily fosphenytoin metabolites including phenytoin metabolites) accounts for approximately 80-90% of elimination; less than 5% excreted unchanged in urine; biliary/fecal excretion minimal.
Renal excretion of unchanged drug accounts for approximately 65-70% of elimination; biliary/fecal excretion is minimal (<5%).
Category D/X
Category C
Anticonvulsant
Anticonvulsant